Tags

Type your tag names separated by a space and hit enter

[A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients].
Zhonghua Yi Xue Za Zhi. 2004 Dec 17; 84(24):2132-6.ZY

Abstract

OBJECTIVE

To evaluate the efficacy and safety of oseltamivir in the treatment of suspected influenza patients.

METHODS

A randomized, open, control and multiple center trial was conducted among 1176 individuals with suspected influenza. They were randomized either to oseltamivir group (oseltamivir 75 mg, twice daily for 5 days) or control group who were given symptom relief medicine.

RESULTS

No difference was found between two groups in influenza symptoms of the patients (P > 0.05) before the treatment. (1) Oseltamivir treatment significantly reduced the duration of fever about 25 hours post treatment. (2) The AUC score of other symptoms was decreased by 160.21 (about 30.21%), and the duration was shorten by 20 hours. (3) The ratio and duration of antibiotic use in oseltamivir group were less than that of control group (P < 0.0001 and P < 0.05). (4) The incident rate of second generation influenza in oseltamivir group was also less than that of control group (P < 0.0001). (5) Secondary complications such as bronchitis, sinusitis and pneumonia occurred 3.23% in Oseltamivir group and 4.16% in the control group (chi(2) = 1.209, P = 0.272). (6) Digestive symptom such as light nausea were occur in patients who took oseltamivir, there was no difference of side effects rate between two groups (5.18% and 4.16%, chi(2) = 0.680, P = 0.410). (7) 75.68% (28) were confirmed with positive result of virus test in 37 suspected influenza patients.

CONCLUSION

Our data suggests that Oseltamivir is effective and well tolerated in suspected influenza patients. It can reduces the duration and severity of influenza symptom and fever, decrease the incidence of suspected influenza in the contacted population, antibiotic using, and with light side-effect.

Authors+Show Affiliations

Deng WW
Department of Respiratory Disease, Shanghai Ruijin Hospital, Shanghai 200025, China.
Li QY
No affiliation info available
Zhong NS
No affiliation info available
"Oseltamivir in the treatment of suspected influenza patients" Study Group
No affiliation info available

MeSH

AcetamidesAdultAntiviral AgentsDrug Administration ScheduleFemaleHumansInfluenza, HumanMaleMiddle AgedOseltamivir

Pub Type(s)

English Abstract
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

chi

PubMed ID

15730636

Citation

Deng, Wei-wu, et al. "[A Multicenter Study of Efficacy and Safety of Oseltamivir in the Treatment of Suspected Influenza Patients]." Zhonghua Yi Xue Za Zhi, vol. 84, no. 24, 2004, pp. 2132-6.
Deng WW, Li QY, Zhong NS, et al. [A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients]. Zhonghua Yi Xue Za Zhi. 2004;84(24):2132-6.
Deng, W. W., Li, Q. Y., & Zhong, N. S. (2004). [A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients]. Zhonghua Yi Xue Za Zhi, 84(24), 2132-6.
Deng WW, et al. [A Multicenter Study of Efficacy and Safety of Oseltamivir in the Treatment of Suspected Influenza Patients]. Zhonghua Yi Xue Za Zhi. 2004 Dec 17;84(24):2132-6. PubMed PMID: 15730636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients]. AU - Deng,Wei-wu, AU - Li,Qing-yun, AU - Zhong,Nan-shan, AU - ,, PY - 2005/2/26/pubmed PY - 2006/5/10/medline PY - 2005/2/26/entrez SP - 2132 EP - 6 JF - Zhonghua yi xue za zhi JO - Zhonghua Yi Xue Za Zhi VL - 84 IS - 24 N2 - OBJECTIVE: To evaluate the efficacy and safety of oseltamivir in the treatment of suspected influenza patients. METHODS: A randomized, open, control and multiple center trial was conducted among 1176 individuals with suspected influenza. They were randomized either to oseltamivir group (oseltamivir 75 mg, twice daily for 5 days) or control group who were given symptom relief medicine. RESULTS: No difference was found between two groups in influenza symptoms of the patients (P > 0.05) before the treatment. (1) Oseltamivir treatment significantly reduced the duration of fever about 25 hours post treatment. (2) The AUC score of other symptoms was decreased by 160.21 (about 30.21%), and the duration was shorten by 20 hours. (3) The ratio and duration of antibiotic use in oseltamivir group were less than that of control group (P < 0.0001 and P < 0.05). (4) The incident rate of second generation influenza in oseltamivir group was also less than that of control group (P < 0.0001). (5) Secondary complications such as bronchitis, sinusitis and pneumonia occurred 3.23% in Oseltamivir group and 4.16% in the control group (chi(2) = 1.209, P = 0.272). (6) Digestive symptom such as light nausea were occur in patients who took oseltamivir, there was no difference of side effects rate between two groups (5.18% and 4.16%, chi(2) = 0.680, P = 0.410). (7) 75.68% (28) were confirmed with positive result of virus test in 37 suspected influenza patients. CONCLUSION: Our data suggests that Oseltamivir is effective and well tolerated in suspected influenza patients. It can reduces the duration and severity of influenza symptom and fever, decrease the incidence of suspected influenza in the contacted population, antibiotic using, and with light side-effect. SN - 0376-2491 UR - https://www.unboundmedicine.com/medline/citation/15730636/[A_multicenter_study_of_efficacy_and_safety_of_oseltamivir_in_the_treatment_of_suspected_influenza_patients]_ DB - PRIME DP - Unbound Medicine ER -